執行摘要 背景：發熱性中性粒細胞減少（NF）發生於早期及轉移性實體瘤、非白血病性血液癌症及急性白血病患者。其粗死亡率為3%至18%。
適應症：Neutropenic Fever
收案條件
納入條件
- ≥18 years
- Tympanic temperature ≥38.3ºC within 24 hours before ED registration
- Last chemotherapy or targeted therapy within 6 weeks for any solid tumour, or in any period following therapies against leukaemia, lymphoma, myelodysplastic syndrome, aplastic anaemia, multiple myeloma, or recipient of HSCT.
排除條件
- \- The decision on how far to apply or deviate from a protocol rests with the clinician. Patients would be excluded from follow up if were unable or unwilling to provide informed consent for data access
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。